Please note that trading solely based on the Biotechnology, Perryville III Building Suite 220 You can unlock it all now. The company traded as high as $26.00 and last traded at $25.87, with a volume of 8186 shares traded. Celldex Therapeutics, Inc. is a biopharmaceutical company. Celldex Therapeutics Inc. disclosed in a document filed with the SEC on Jun 11 that Young Diane C. (SVP, Chief Medical Officer) bought a total of 2,115 shares of the company’s common stock. Shares of Celldex Therapeutics (NASDAQ:CLDX), a clinical-stage biotechnology company, are rising in response to insider stock purchases and large equity stakes acquired by … Just click the link See Celldex Therapeutics Stock News NASDAQ:CLDX. CLDX | Complete Celldex Therapeutics Inc. stock news by MarketWatch. CLDX's rank also includes a long-term technical score of 83. Industry: Share Price & News. Surged on Thursday, Why Shares of Celldex Therapeutics, Inc. Sailed Higher Today, Why Celldex Therapeutics, Inc. Fell on Monday, Why Celldex Therapeutics Inc. Shares Jumped on Wednesday, Why Celldex Therapeutics Stock Is Cratering Today, Why Celldex Therapeutics Stock Crashed in February, Why Celldex Therapeutics Stock Reversed Course in November, Copyright, Trademark and Patent Information. HAMPTON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company’s participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conference, March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company’s participation in a fireside chat All 'A' Rated Buy Stocks, • 3 Electric Vehicle Supplier Stocks to Consider Adding to Your Portfolio, • Video Game Industry in 2021: The Complete Investors Guide, Celldex Therapeutics To Test CDX-0159 In Chronic Itchy Skin Disorder, Celldex to expand development of CDX-0159 into prurigo nodularis, Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN), Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference, The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout, Celldex Therapeutics Inc (CLDX) Stock Price | Nasdaq, Celldex Therapeutics Inc (CLDX) Stock Quote, History and News - Yahoo Finance, Celldex Therapeutics Inc (CLDX) Stock Price and Basic Information | MarketWatch. ET. Celldex Therapeutics News: This is the News-site for the company Celldex Therapeutics on Markets Insider. Considering analysts have assigned the stock a price target range of $22-$32 as the low and high respectively, we find the trailing 12-month average consensus price target to be $26.33. The trade occurred on Jun 11 and was made at $4.73 per share for $10004.0. Get the latest Celldex Therapeutics (CLDX) stock price quote with real-time news, financials, charts and other important investing information. CLDX earnings call for the period ending December 31, 2018. Real time Celldex Therapeutics (CLDX) stock price quote, stock graph, news & analysis. Celldex Therapeutics Inc. (NASDAQ:CLDX) went down by -3.24% from its latest closing price compared to the recent 1-year high of $23.40. Celldex Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 12.78% of Pharmaceutical Products stocks. ET. A big loss despite a lack of news for the precommercial biotech. above. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference. A rotten week for biotech didn't end well for Celldex. Celldex Therapeutics Inc (NASDAQ: CLDX) will expand the clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin. The clinical-stage biotech stretched out its cash in the fourth quarter by cost reductions and took the necessary moves in the following months to retain its listing on the Nasdaq stock exchange. Copyright © 2021. Get the latest Celldex Therapeutics, Inc. (CLDX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. United States Health Care The clinical-stage biotech continued to conserve cash while conducting multiple clinical studies in the second quarter. Get the latest news and real-time alerts from Celldex Therapeutics, Inc. (CLDX) stock at Seeking Alpha. View the latest Celldex Therapeutics Inc. (CLDX) stock price, news, historical charts, analyst ratings and financial information from WSJ. There's nothing to get excited about with this clinical-stage biotech stock's double-digit-percentage gain. CLDX's price/sales ratio is 230.1; that's higher than the P/S ratio of 97.71% of US stocks. Latest Share Price and Events Stable Share Price : CLDX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week. Celldex Therapeutics Inc.’s Net Margin is presently recorded at -1423.96. CLDX has a higher number of analysts covering the stock than 11.89% of stocks in the mid market cap category. Here's why shares of these drugmakers seem unstoppable this year. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Get the latest Celldex Therapeutics, Inc. (CLDX) stock news and headlines to help you in your trading and investing decisions. Investors pile in ahead of a binary event. What our community thinks about Celldex Therapeutics, The single most important factor in a company's success is the team that's leading the company, 3 Healthcare Stocks That Surged Last Week, Here's Why Celldex Therapeutics Stock Is Soaring Today, Celldex Therapeutics Inc (CLDX) Q2 2019 Earnings Call Transcript, Celldex Therapeutics Keeps Up Its Penny-Pinching and Pipeline Progress, Celldex Therapeutics Continues to Stretch Out Its Cash and Advance Its Pipeline, Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling, Celldex Therapeutics, Inc (CLDX) Q4 2018 Earnings Conference Call Transcript, Here's Why Celldex Therapeutics Sank on Friday, Why Celldex Therapeutics Is Jumping Today, Here's Why Celldex Therapeutics, Inc. Press Release reported on 11/30/20 that Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference. Sign Up to See Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s traded shares stood at 516,171 during the last session, with the company’s beta value hitting 3.06. Markets Insider. Its … ET. Ratings...FREE! Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Celldex and other traded companies coverage. CLDX earnings call for the period ending June 30, 2019. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Shares of Celldex Therapeutics (NASDAQ:CLDX), a clinical-stage biotechnology company, are rising in response to insider stock purchases and large equity stakes acquired by … HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. Celldex Therapeutics, Inc. stock has risen 838.05% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives CLDX stock a score of 74 out of a possible 100.. That rank is chiefly influenced by a short-term technical score of 93. Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s traded shares stood at 516,171 during the last session, with the company’s beta value hitting 3.06. Just enter your email address below. Researching Celldex Therapeutics (NASDAQ:CLDX) stock? In December last year, the company dosed the first patient in a chronic inducible urticaria study. Get Celldex Therapeutics Inc (CLDX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Operating Margin for any stock indicates how profitable investing would be, and Celldex Therapeutics Inc. [CLDX] shares currently have an operating margin of -1526.03. A replay will be available for fourteen days following the event. Following the transaction, the insider now directly holds 2115.0 shares of the CLDX stock. nasdaq.com - September 29 at 12:48 PM: Stock Alert: Celldex Therapeutics Climbs To New 52-week High With a one year PEG ratio of 803.9, Celldex Therapeutics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.99% of US stocks. ET. Get the latest news and real-time alerts from Celldex Therapeutics, Inc. (CLDX) stock at Seeking Alpha. Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! appreciate its future potential. The stock had previously closed at $25.25. Sector: Initial data is expected at the end of the first quarter of 2021. Stable Share Price: CLDX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week. The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts 12:25pm, Tuesday, 23'rd Feb 2021. CLDX Stock Summary. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Separately, Lifesci Capital reaffirmed an “outperform” rating on shares of Celldex Therapeutics […] www.celldex.com. Find the latest news headlines from Celldex Therapeutics, Inc. (CLDX) at Nasdaq.com. The company is evaluating CDX-0159 in two ongoing Phase 1b trials in patients with chronic spontaneous urticaria and chronic inducible urticaria. Celldex is offering 13,377,926 shares of its common stock, par value $0.001 per share, at a price to the public of $9.75 per share. Real time Celldex Therapeutics (CLDX) stock price quote, stock graph, news & analysis. Hives (urticaria) are red, itchy welts that result from a skin reaction. A big gain on no news for this clinical-stage biotech. Celldex's highly anticipated breast cancer drug fails to hit the mark in a midstage trial. Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s beta value is holding at 2.68, while the average true range (ATR) indicator is currently reading 1.5. Get the latest Celldex Therapeutics, Inc. (CLDX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. In comparing Celldex Therapeutics, Inc. (CLDX)’s stock with other industry players reveals that stock’s current price change of +4.01% and that of +940.08% over the past 12 months is in better position with that of Bristol-Myers Squibb Company (BMY) which saw its stock price raised by 1.84% in the last trading and went through a decline of -0.12% in past 12-month trading. Celldex Therapeutics, Inc. stock has gained 896.61% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives CLDX stock a score of 71 out of a possible 100.. That rank is influenced by a short-term technical score of 84. Business Insider . HAMPTON, N.J., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation. Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages. A high-level overview of Celldex Therapeutics, Inc. (CLDX) stock. CLDX's rank also includes a long-term technical score of 86. The clinical-stage biotech effectively conserved cash in the first quarter, thanks to cost cuts following last year's pipeline setback with experimental cancer drug glemba. Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s beta value is holding at 2.68, while the average true range (ATR) indicator is currently reading 1.5. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. View real-time stock prices and stock quotes for a full financial overview. Join. The MarketWatch News Department was not involved in the creation of this content. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in … Current stock quote for Celldex Therapeutics Inc. ( CLDX ) including financial statements, level 2 data, and the latest Biotechnology news, research, and investment community discussion Mast cells through their interactions with sensory neurons and other immune cells are believed to play an important role in ... HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. Primary metrics and data points about Celldex Therapeutics. Celldex Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 12.78% of Pharmaceutical Products stocks. A chronic spontane... Celldex Therapeutics (CLDX) will expand clinical development of CDX-0159 into prurigo nodularis ((PN)), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its... --Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation----Potential to expand future CDX-0159 development beyond chronic urticarias to chronic pruritic diseases and other significant indications driven by itch and neuroinflammation-- HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will expand clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin. In a Phase 1a single-dose, healthy volunteer study, CDX-0159 demonstrated durable plasma tryptase reductions indicative of systemic mast cell suppression/ablation. Celldex Therapeutics Inc. [CLDX]: An insightful look at the core fundamentals. Find the latest Celldex Therapeutics, Inc. (CLDX) stock quote, history, news and other vital information to help you with your stock trading and investing. HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. Market data powered by FactSet and Web Financial Group. The ratio of debt to operating expenses for Celldex Therapeutics Inc is higher than it is for about just 9.16% of US stocks. Celldex Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s share price reached a new 52-week high during mid-day trading on Wednesday . Below are the latest news stories about Celldex Therapeutics Inc that investors may wish to consider to help them evaluate CLDX as an investment opportunity. About Us Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Stocks with similar financial metrics, market capitalization, and price volatility to Celldex Therapeutics Inc are. The company’s stock price has collected 2.45% of gains in the last five trading sessions. View the latest Celldex Therapeutics Inc. (CLDX) stock price, news, historical charts, analyst ratings and financial information from WSJ.